Does silent myocardial infarction add prognostic value in ST-elevation myocardial infarction patients without a history of prior myocardial infarction? Insights from the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) Trial

American Heart Journal

Volumn 160, Issue 4, 2010, Pages 671-677

  Toma, Mustafa ^a   Fu, Yuling ^a   Ezekowitz, Justin A ^a   McAlister, Finlay A ^a   Westerhout, Cynthia M ^a   Granger, Christopher B ^b   Armstrong, Paul W ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PEXELIZUMAB; PLACEBO; MONOCLONAL ANTIBODY; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; FEMALE; HAZARD RATIO; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MULTICENTER STUDY; PRIORITY JOURNAL; PROGNOSIS; Q WAVE; SHOCK; SILENT MYOCARDIAL INFARCTION; ST SEGMENT ELEVATION; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; COMPARATIVE STUDY; DOSE RESPONSE; ELECTROCARDIOGRAPHY; MIDDLE AGED; MORTALITY; MYOCARDIAL INFARCTION; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SECONDARY PREVENTION; SURVIVAL RATE; TREATMENT OUTCOME; TRENDS;

AGED; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); RISK FACTORS; SECONDARY PREVENTION; SINGLE-CHAIN ANTIBODIES; SURVIVAL RATE;

EID: 77957837413     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2010.06.054     Document Type: Article

References (20)

1. Wong C.K., Gao W., and Raffel O.C. Initial Q waves accompanying ST-segment elevation at presentation of acute myocardial infarction and 30-day mortality in patients given streptokinase therapy: an analysis from HERO-2 Lancet 367 2006 2061 2067
2. LaBounty T., Gurm H.S., and Goodman S.G. Predictors and implications of Q-waves in ST-elevation acute coronary syndromes Am J Med 122 2009 144 151
3. McDonald M.A., Fu Y., and Zeymer U. Adverse outcomes in fibrinolytic-based facilitated percutaneous coronary intervention: insights from the ASSENT-4 PCI electrocardiographic substudy Eur Heart J 29 2008 871 879
4. Armstrong P.W., Fu Y., and Westerhout C.M. Baseline Q-wave surpasses time from symptom onset as a prognostic marker in ST-segment elevation myocardial infarction patients treated with primary percutaneous coronary intervention J Am Coll Cardiol 53 2009 1503 1509
5. de T.A., Boersma E., and Kors J.A. Incidence of recognized and unrecognized myocardial infarction in men and women aged 55 and older: the Rotterdam Study Eur Heart J 27 2006 729 736
6. Jonsdottir L.S., Sigfusson N., and Sigvaldason H. Incidence and prevalence of recognised and unrecognised myocardial infarction in women. The Reykjavik Study Eur Heart J 19 1998 1011 1018
7. Sigurdsson E., Thorgeirsson G., and Sigvaldason H. Unrecognized myocardial infarction: epidemiology, clinical characteristics, and the prognostic role of angina pectoris. The Reykjavik Study Ann Intern Med 122 1995 96 102
8. Armstrong P.W., Granger C.B., and Adams P.X. Pexelizumab for acute ST-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention: a randomized controlled trial JAMA 297 2007 43 51
9. Anderson W.D., Wagner N.B., and Lee K.L. Evaluation of a QRS scoring system for estimating myocardial infarct size. VI. Identification of screening criteria for non-acute myocardial infarcts Am J Cardiol 61 1988 729 733
10. Wagner G.S., Freye C.J., and Palmeri S.T. Evaluation of a QRS scoring system for estimating myocardial infarct size. I. Specificity and observer agreement Circulation 65 1982 342 347
11. Sevilla D., Wagner N., and Anderson W.D. Sensitivity of a set of myocardial infarction screening criteria in patients with anatomically documented single and multiple infarcts Am J Cardiol 66 1990 792 795
12. Kannel W.B., and Abbott R.D. Incidence and prognosis of unrecognized myocardial infarction. An update on the Framingham study N Engl J Med 311 1984 1144 1147
13. Andrews J., French J.K., and Manda S.O. New Q waves on the presenting electrocardiogram independently predict increased cardiac mortality following a first ST-elevation myocardial infarction Eur Heart J 21 2000 647 653
14. Birnbaum Y., Chetrit A., and Sclarovsky S. Abnormal Q waves on the admission electrocardiogram of patients with first acute myocardial infarction: prognostic implications Clin Cardiol 20 1997 477 481
15. Sheifer S.E., Manolio T.A., and Gersh B.J. Unrecognized myocardial infarction Ann Intern Med 135 2001 801 811
16. Ammar K.A., Makwana R., and Redfield M.M. Unrecognized myocardial infarction: the association with cardiopulmonary symptoms and mortality is mediated via echocardiographic abnormalities of global dysfunction instead of regional dysfunction: the Olmsted County Heart Function Study Am Heart J 151 2006 799 805
17. Kloner R.A., and Jennings R.B. Consequences of brief ischemia: stunning, preconditioning, and their clinical implications: part 2 Circulation 104 2001 3158 3167
18. Habib G.B., Heibig J., and Forman S.A. Influence of coronary collateral vessels on myocardial infarct size in humans. Results of phase I thrombolysis in myocardial infarction (TIMI) trial. The TIMI Investigators Circulation 83 1991 739 746
19. Spencer F.A., Meyer T.E., and Gore J.M. Heterogeneity in the management and outcomes of patients with acute myocardial infarction complicated by heart failure: the National Registry of Myocardial Infarction Circulation 105 2002 2605 2610
20. O'Connor C.M., Hathaway W.R., Bates E.R., Leimberger J.D., Sigmon K.N., and Kereiakes D.J. Clinical characteristics and long-term outcome of patients in whom congestive heart failure develops after thrombolytic therapy for acute myocardial infarction: development of a predictive model Am Heart J 133 1997 663 673